

Ramsey C Cheung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2496018/publications.pdf>

Version: 2024-02-01

98
papers

6,519
citations

172207

29
h-index

69108

77
g-index

98
all docs

98
docs citations

98
times ranked

7910
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e610-e613.	2.4	23
2	Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1803-1812.e5.	2.4	46
3	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	2.4	4
4	ALT Levels in Treatment-Naive, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A US Nationwide Study. <i>Digestive Diseases</i> , 2022, 40, 497-505.	0.8	0
5	Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. <i>Journal of Hepatology</i> , 2022, 76, 63-74.	1.8	22
6	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	1.9	7
7	County-Level Variation in Cirrhosis-Related Mortality in the US, 1999-2019. <i>JAMA Network Open</i> , 2022, 5, e2146427.	2.8	0
8	Nonalcoholic Fatty Liver Disease in Children: where are we?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
9	2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2809-2817.e28.	2.4	255
10	Global trends and the impact of chronic hepatitis B and C on disability-adjusted life years. <i>Liver International</i> , 2022, 42, 2145-2153.	1.9	7
11	Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 223, 139-146.	1.9	2
12	Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. <i>Journal of Medical Virology</i> , 2021, 93, 1449-1458.	2.5	450
13	Ethnicity-Specific Differences in Liver Transplant Outcomes Among Adults With Primary Sclerosing Cholangitis: 2005-2017 United Network for Organ Sharing/Organ Procurement and Transplantation Network. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 30-36.	0.4	5
14	Water-assisted colonoscopy: an international modified Delphi review on definitions and practice recommendations. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 1411-1420.e18.	0.5	33
15	High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 767-774.	1.4	6
16	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	1.9	14
17	In Reply. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 129b-130.	1.2	1
18	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. <i>Hepatology International</i> , 2021, 15, 366-379.	1.9	71

#	ARTICLE	IF	CITATIONS
19	NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea. <i>Digestive Diseases</i> , 2021, 39, 634-645.	0.8	29
20	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. <i>American Journal of Gastroenterology</i> , 2021, 116, 1264-1273.	0.2	12
21	Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2092-2100.	1.1	30
22	Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	3
23	Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 1885-1895.	0.2	14
24	A population-based US study of hepatitis C diagnosis rate. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	4
25	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 1922-1932.	1.9	15
26	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	1.9	40
27	Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. <i>Hepatology</i> , 2021, 74, 656-666.	3.6	31
28	The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2068-2078.	0.2	16
29	Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease. <i>American Journal of Medicine</i> , 2021, 134, 882-892.	0.6	3
30	Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2021, 93, 6257-6266.	2.5	0
31	Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1100-1109.	1.9	32
32	Surveillance of patients with cirrhosis remains suboptimal in the United States. <i>Journal of Hepatology</i> , 2021, 75, 856-864.	1.8	20
33	Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999-2016. <i>Journal of Infectious Diseases</i> , 2020, 221, 408-418.	1.9	19
34	Chronic Hepatitis B Prevalence Among Foreign-Born and U.S.-Born Adults in the United States, 1999-2016. <i>Hepatology</i> , 2020, 71, 431-443.	3.6	82
35	A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1520-1528.	1.1	25
36	Race/Ethnicity and Insurance-Specific Disparities in In-Hospital Mortality Among Adults with Primary Biliary Cholangitis: Analysis of 2007-2014 National Inpatient Sample. <i>Digestive Diseases and Sciences</i> , 2020, 65, 406-415.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Preoperative Endoscopic Findings in Veterans Undergoing Bariatric Surgery: Prevalence and Predictors of Barrett's Esophagus. <i>Obesity Surgery</i> , 2020, 30, 657-663.	1.1	14
38	Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. <i>Hepatology</i> , 2020, 71, 1910-1922.	3.6	70
39	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	2.9	30
40	Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 406-419.	0.8	19
41	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. <i>BMC Medicine</i> , 2020, 18, 200.	2.3	25
42	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00196.	1.3	15
43	Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world. <i>Liver International</i> , 2020, 40, 3145-3145.	1.9	3
44	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	1.9	38
45	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 739-752.	3.7	481
46	The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. <i>Hepatology International</i> , 2020, 14, 259-269.	1.9	56
47	Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. <i>Liver International</i> , 2020, 40, 1052-1061.	1.9	20
48	Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. <i>JAMA Network Open</i> , 2020, 3, e201844.	2.8	42
49	Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2022388.	2.8	26
50	Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1039-1052.	3.7	70
51	Letter to the Editor: Prevalence of NAFLD in China: What Did We Learn From the Recent Meta-Analysis?. <i>Hepatology</i> , 2019, 70, 2238-2239.	3.6	2
52	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	1.9	27
53	Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection. <i>Current Hepatology Reports</i> , 2019, 18, 322-330.	0.4	1
54	Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?. <i>Journal of Hepatology</i> , 2019, 71, 240-242.	1.8	7

#	ARTICLE	IF	CITATIONS
55	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 473-485.	1.8	62
56	Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 296-304.	0.7	23
57	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999â€“2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 389-398.	3.7	616
58	Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2019, 91, 1288-1294.	2.5	14
59	More Severe Deficits in Performance Status at Time of Liver Transplant is Associated With Significantly Higher Risk of Death Following Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e392-e399.	1.1	10
60	Hepatitis B and renal function: A matched study comparing nonâ€“hepatitis B, untreated, treated and cirrhotic hepatitis patients. <i>Liver International</i> , 2019, 39, 655-666.	1.9	5
61	Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2019, 114, 80-88.	0.2	28
62	Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 957-967.e7.	2.4	28
63	Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 948-956.e1.	2.4	38
64	Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 65-70.	1.1	23
65	Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000207.	1.1	11
66	African-Americans with Cirrhosis Are Less Likely to Receive Endoscopic Variceal Screening Within One Year of Cirrhosis Diagnosis. <i>Journal of Racial and Ethnic Health Disparities</i> , 2018, 5, 860-866.	1.8	8
67	Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000209.	1.1	13
68	Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. <i>PLoS ONE</i> , 2017, 12, e0173499.	1.1	203
69	Colonoscopy with polypectomy is associated with a low rate of complications in patients with cirrhosis. <i>Endoscopy International Open</i> , 2016, 04, E947-E952.	0.9	11
70	Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2016, 61, 636-645.	1.1	80
71	Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. <i>Journal of Hepatology</i> , 2016, 64, 326-332.	1.8	21
72	The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 873-880.	1.3	31

#	ARTICLE	IF	CITATIONS
73	Diabetes Mellitus, and Not Obesity, Is Associated with Lower Survival Following Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1036-1044.	1.1	42
74	Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. <i>Gastroenterology</i> , 2015, 148, 547-555.	0.6	1,506
75	Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2813-2824.	1.1	56
76	Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2005-2014.e3.	2.4	93
77	Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1045-1051.	1.1	21
78	Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.. <i>Hepatology</i> , 2014, 59, 2188-2195.	3.6	616
79	Increased Long-term Survival Among Patients With Hepatocellular Carcinoma After Implementation of Model for End-stage Liver Disease Score. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1534-1540.e1.	2.4	16
80	Assessment and Utilization of Rapid Virologic Response in US Veterans With Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 264-270.	1.1	4
81	Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3011-3016.	1.1	24
82	Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients Undergoing Interferon- α and Ribavirin Therapy: A Prospective Evaluation. <i>American Journal of Gastroenterology</i> , 2011, 106, 2123-2132.	0.2	19
83	Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1744-1751.	1.1	14
84	The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. <i>Quality of Life Research</i> , 2008, 17, 715-724.	1.5	17
85	Diagnostic markers for hepatitis virus infection. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 303-314.	1.6	1
86	Can We Predict the Degree of Fibrosis in Chronic Hepatitis C Patients Using Routine Blood Tests in Our Daily Practice?. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 827-834.	1.1	41
87	Positive CAGE Screen Correlates with Cirrhosis in Veterans with Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2564-2569.	1.1	3
88	National Multicenter Study of HIV Testing and HIV Seropositivity in Patients With Chronic Hepatitis C Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 732-739.	1.1	12
89	The Impact of Chronic Hepatitis C and Comorbid Psychiatric Illnesses on Health-related Quality of Life. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 528-534.	1.1	39
90	Effectiveness of a Screening Program for Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2006, 51, 976-981.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection. <i>American Journal of Gastroenterology</i> , 2005, 100, 1772-1779.	0.2	168
92	High mortality rate in patients with advanced liver disease independent of exposure to general anesthesia. <i>Journal of Clinical Anesthesia</i> , 2005, 17, 172-176.	0.7	7
93	Practice Patterns and Treatment Outcomes in the Management of Chronic Hepatitis C (CHC) Infection in a Large Managed Care Cohort. <i>American Journal of Gastroenterology</i> , 2005, 100, S283.	0.2	1
94	The Impact of Hepatitis C Status on Postoperative Outcome. <i>Anesthesia and Analgesia</i> , 2003, 97, 550-554.	1.1	7
95	Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2002, 97, 2640-2646.	0.2	75
96	Viral Hepatitis and Other Infectious Diseases in a Homeless Population. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 476-480.	1.1	114
97	Epidemiology of hepatitis C virus infection in American veterans. <i>American Journal of Gastroenterology</i> , 2000, 95, 740-747.	0.2	108
98	Complications of Liver Biopsy. , 0 , 72-75.		0